Safety and efficacy of neoadjuvant pembrolizumab in mismatch repair deficient localized/locally advanced solid tumors.

被引：7
|
作者：
Ludford, Kaysia
Raghav, Kanwal Pratap Singh
Murphy, Mariela A. Blum
Fleming, Nicole D.
Nelson, Douglas A.
Lee, Michael Sangmin
Smaglo, Brandon George
You, Y. Nancy
Tillman, Matthew Murray
Kamiya-Matsuoka, Carlos
Thirumurthi, Selvi
Messick, Craig
Johnson, Benny
Sanchez, Eduardo Vilar
Dasari, Arvind
Thomas, Jane V.
Foo, Wai Chin
Qiao, Wei
Kopetz, Scott
Overman, Michael J.
机构：
[1] Univ Texas MD Anderson, Houston, TX USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, The Woodlands, TX USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Colon & Rectal Surg, Houston, TX 77030 USA
[5] Univ Texas MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA
[6] Univ Texas MD Anderson Canc Ctr, Dept Gastroenterol, Houston, TX 77030 USA
[7] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA
[8] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA
[9] Univ Texas MD Anderson Canc Ctr, Dept Clin Canc Prevent, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.2520
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2520
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Immunotherapy in Localized Microsatellite Instability-High/Mismatch Repair Deficient Solid Tumors: Are We Ready for a New Standard of Care?
    Ciombor, Kristen K.
    Eng, Cathy
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (12) : 2138 - +
  • [42] Pembrolizumab in microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) advanced solid tumors: An update of the phase II KEYNOTE-158 trial
    Maio, M.
    Ascierto, P. A.
    Motola Kuba, D.
    Penel, N.
    Cassier, P. A.
    Bariani, G. M.
    De Jesus-Acosta, A.
    Doi, T.
    Longo Munoz, F.
    Miller, W. H.
    Oh, D-Y.
    Gottfried, M.
    Yao, L.
    Jin, F. J.
    Gozman, A.
    Marabelle, A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S589 - S590
  • [43] Efficacy, safety, tolerability and price of newly approved drugs in solid tumors.
    Barnes, Tristan Alexandra
    Amir, Eitan
    Templeton, Arnoud J.
    Garcia, Susana Gomez
    Navarro, Beatriz
    Seruga, Bostjan
    Ocana, Alberto
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [44] Real-world efficacy and safety of immune checkpoint inhibitors in microsatellite unstable or mismatch repair deficient gastrointestinal tumors
    Martinez Lago, N.
    Cousillas Castineiras, A.
    Fernandez Montes, A.
    Carnero Lopez, B.
    Gonzalez Villarroel, P.
    Vazquez-Rivera, F.
    Alonso de Castro, B.
    Gonzalez, B.
    Salgado Fernandez, M.
    Gallardo Martin, E.
    Reboredo Rendo, C.
    Mateos Gonzalez, M.
    de la Camara Gomez, J.
    Romero Reinoso, C.
    Mendez Mendez, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S107 - S107
  • [45] Clinical status and future prospects of neoadjuvant immunotherapy for localized mismatch repair-deficient cancers: a review
    Li, Jian
    INTERNATIONAL JOURNAL OF SURGERY, 2024, 110 (09) : 5722 - 5732
  • [46] Mismatch Repair System Deficiency Is Associated With Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer
    Meillan, Nicolas
    Vernerey, Dewi
    Lefevre, Jeremie H.
    Manceau, Gilles
    Svrcek, Magali
    Augustin, Jeremy
    Flejou, Jean-Francois
    Lascols, Olivier
    Simon, Jean-Marc
    Cohen, Romain
    Maingon, Philippe
    Bachet, Jean-Baptiste
    Huguet, Florence
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (04): : 824 - 833
  • [47] Complete pathologic response (pCR) following neoadjuvant pembrolizumab monotherapy in treatment-naive locally advanced, mismatch repair protein-deficient (dMMR) colonic cancer: a case report and literature review
    Tan-Garcia, Alfonso
    Wang, Lai Mun
    Ngu, James Chi-Yong
    Goh, Lynne
    ACTA ONCOLOGICA, 2022, 61 (06) : 780 - 784
  • [48] Clinical and molecular features of responders to PD-1 blockade for patients with microsatellite instability high or mismatch repair deficient advanced gastrointestinal tumors.
    Chida, Keigo
    Kawazoe, Akihito
    Kawazu, Masahito
    Nakamura, Yoshiaki
    Suzuki, Toshihiro
    Kitano, Shigehisa
    Nakatsura, Tetsuya
    Kuwata, Takeshi
    Shitara, Kohei
    Ikeda, Masafumi
    Yoshino, Takayuki
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [49] Cure without Surgery and Chemoradiation in locally advanced, Mismatch-repair-deficient Rectal Cancer?
    Rink, Andreas D.
    Kasper, Stefan
    COLOPROCTOLOGY, 2022, 44 (05) : 357 - 360
  • [50] PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer
    Cercek, Andrea
    Lumish, Melissa
    Sinopoli, Jenna
    Weiss, Jill
    Shia, Jinru
    Lamendola-Essel, Michelle
    El Dika, Imane H.
    Segal, Neil
    Shcherba, Marina
    Sugarman, Ryan
    Stadler, Zsofia
    Yaeger, Rona
    Smith, J. Joshua
    Rousseau, Benoit
    Argiles, Guillem
    Patel, Miteshkumar
    Desai, Avni
    Saltz, Leonard B.
    Widmar, Maria
    Iyer, Krishna
    Zhang, Janie
    Gianino, Nicole
    Crane, Christopher
    Romesser, Paul B.
    Pappou, Emmanouil P.
    Paty, Philip
    Garcia-Aguilar, Julio
    Gonen, Mithat
    Gollub, Marc
    Weiser, Martin R.
    Schalper, Kurt A.
    Diaz, Luis A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (25): : 2363 - 2376
12345